Supplementary Figure legends 1a-j

Slides:

Advertisements

Similar presentations

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Национальная процедура одобрения и регистрации проектов (программ) международной технической помощи (исключая представление информации об организации и.

The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study Ying Li, Sheng Zhang, Xi.

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Supporting Information for Meta-analysis

Supporting Information for Meta-analysis

Supplementary Figure S2

Supplementary Figure 1 CD45 CD14 FSC CD123 HLA-DR CD11c Lineage

Volume 146, Issue 7, Pages e3 (June 2014)

A B C Supplementary figure S7

An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors Jingqin Luo, Shuzhen Liu, Samuel Leung,

WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)

Quantitative Fluorescence in Situ Hybridization and its Ability to Predict Bladder Cancer Recurrence and Progression to Muscle-Invasive Bladder Cancer

Volume 5, Issue 6, Pages (June 2004)

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts Rintaro Noro,

Survival of patients with distal esophageal and gastric cardia tumors: A population- based analysis of gastroesophageal junction carcinomas Bryan A. Whitson,

Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer Marco Alifano, MD, PhD, Pierre.

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Arjun Pennathur, MD, Liqiang Xi, MD, Virginia R. Litle, MD, William E

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer Patrick Wald,

Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities Martin Lauss, Jeremie Nsengimana, Johan Staaf, Julia Newton-Bishop, Göran.

Diagnostic and Prognostic Value of Metastasis Inducer S100A4 Transcripts in Plasma of Colon, Rectal, and Gastric Cancer Patients Ulrike Stein, Susen.

Volume 146, Issue 7, Pages e3 (June 2014)

Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study Thomas K. Eigentler, Ulrike Leiter, Hans-Martin Häfner,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

The Effects of Interleukin 10 and Interferon γ Cytokine Gene Polymorphisms on Survival after Autologous Bone Marrow Transplantation for Patients with.

Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence Xiaoyu Qu, Claudio Jeldres, Lena Glaskova, Cynthia.

Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database

Meta-analysis of all patients

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Development of a Diagnostic Microarray Assay to Assess the Risk of Recurrence of Prostate Cancer Based on PITX2 DNA Methylation Philipp Schatz, Dimo.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Solving Equations 3x+7 –7 13 –7 =.

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Erratum Journal of Thoracic Oncology

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases Hironori Uruga, MD, PhD, Emine Bozkurtlar,

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective.

It’s All in the “Swerve of the Curve”

Individuals (dots) colored according to results of hierarchical clustering of copy number estimates (as described in Supplementary Text) for IGHV

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Supplementary Figure S3

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma.

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features Min-Woong Kang, MD, PhD, Eung-Sirk.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Supplementary Figure S5

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Survival in patients with colorectal cancer diagnosed by screening colonoscopy Kilian Friedrich, MD, Ludwig Grüter, MD, Daniel Gotthardt, MD, PhD, Christoph.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Supplementary Figure legends 1a-j Title: In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients Journal: Gastric Cancer Authors: Yasutoshi Kuboki, Christoph A. Schatz, Karl Koechert, Sabine Schubert, Janine Feng, Sabine Wittemer-Rump, Karl Ziegelbauer, Thomas Krahn, Akiko Kawano Nagatsuma, Atsushi Ochiai Corresponding author: Christoph A. Schatz, email: christoph.schatz@bayer.com Supplementary Figure legends 1a-j Figure 1a Kaplan-Meier plot for RFS by macroscopic classification Figure 1b Kaplan-Meier plot for RFS by FGFR2 RNAscope® for tumor stage I Figure 1c Kaplan-Meier plot for RFS by FGFR2 RNAscope® for tumor stage II Figure 1d Kaplan-Meier plot for RFS by FGFR2 RNAscope® for tumor stage III Figure 1e Kaplan-Meier plot for RFS by FGFR2 RNAscope® for tumor stage IV Figure 1f Kaplan-Meier plot for OS by macroscopic classification Figure 1g Kaplan-Meier plot for OS by FGFR2 RNAscope® for tumor stage I Figure 1h Kaplan-Meier plot for OS by FGFR2 RNAscope® for tumor stage II Figure 1i Kaplan-Meier plot for OS by FGFR2 RNAscope® for tumor stage III Figure 1j Kaplan-Meier plot for OS by FGFR2 RNAscope® for tumor stage IV

Supplementary Figure 1a Title: In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients Journal: Gastric Cancer Authors: Yasutoshi Kuboki, Christoph A. Schatz, Karl Koechert, Sabine Schubert, Janine Feng, Sabine Wittemer-Rump, Karl Ziegelbauer, Thomas Krahn, Akiko Kawano Nagatsuma, Atsushi Ochiai Corresponding author: Christoph A. Schatz, email: christoph.schatz@bayer.com

Supplementary Figure 1b

Supplementary Figure 1c

Supplementary Figure 1d

Supplementary Figure 1e

Supplementary Figure 1f

Supplementary Figure 1g

Supplementary Figure 1h

Supplementary Figure 1i

Supplementary Figure 1j